Wernicke-Korsakoff Syndrome

Wernicke encephalopathy and Korsakoff syndrome together represent the spectrum of thiamine (vitamin B1) deficiency disease — Wernicke being the acute, partially reversible phase and Korsakoff being the chronic, often irreversible amnestic syndrome. Both are common causes of preventable neurologic morbidity, and both have distinctive neuropathology centered on the mammillary bodies, periaqueductal gray, and medial thalami. The disease is dramatically responsive to immediate parenteral thiamine if recognized; under-treated or unrecognized cases produce devastating permanent cognitive deficits. This page covers the neuropathology and clinical features.

Pathology of Wernicke Encephalopathy

Distribution

  • Mammillary bodies: the most characteristic site; symmetric necrosis with hemorrhage acutely, atrophy chronically.
  • Periaqueductal gray: around the cerebral aqueduct.
  • Floor of the fourth ventricle: around CN VI nucleus, vestibular nuclei.
  • Medial thalamus: dorsomedial, anterior nuclei.
  • Hypothalamus.
  • Midbrain.
  • The pattern reflects regions with high oxidative metabolism dependent on thiamine.

Histology

  • Vascular dilation and congestion.
  • Small punctate hemorrhages (petechiae).
  • Edema.
  • Astrocyte and microglial reactions.
  • Endothelial proliferation.
  • Eventually neuronal loss with reactive gliosis.
  • Chronic stage: brown discoloration (hemosiderin) and atrophy of mammillary bodies.

Clinical Features of Wernicke Encephalopathy

Classical Triad (Often Incomplete)

  • Ophthalmoplegia: bilateral abducens (CN VI) palsy, nystagmus, sometimes vertical gaze palsy.
  • Ataxia: cerebellar / vestibular; gait predominantly.
  • Confusion / encephalopathy: disorientation, drowsiness.

The complete triad occurs in only ~10% of cases. Most patients have one or two features; confusion is most common.

Other Features

  • Hypothermia (hypothalamic).
  • Hypotension (autonomic).
  • Tachycardia.
  • Peripheral neuropathy (often coexists).
  • Coma in severe cases.

Risk Factors

  • Chronic alcoholism: most common (poor nutrition + reduced absorption).
  • Severe malnutrition: anorexia, severe weight loss, eating disorders.
  • Bariatric surgery: especially gastric bypass; thiamine deficiency in months to years.
  • Hyperemesis gravidarum: prolonged vomiting in pregnancy.
  • Prolonged IV nutrition without thiamine supplementation.
  • Severe ICU illness.
  • Cancer (especially with cachexia).
  • Glucose loading without thiamine: can precipitate Wernicke encephalopathy in at-risk patients.

Imaging

  • T2/FLAIR hyperintensity in periaqueductal gray, medial thalami, mammillary bodies, floor of fourth ventricle.
  • Mammillary body enhancement in acute phase.
  • Mammillary body atrophy in chronic phase.
  • DWI: restricted diffusion in acute phase.

Treatment

  • IV thiamine BEFORE glucose: critical. Glucose without thiamine can precipitate or worsen Wernicke encephalopathy.
  • High-dose parenteral thiamine: 500 mg IV three times daily for 2-3 days, then 250 mg IV daily for 3-5 days, then oral.
  • Oral thiamine alone is inadequate for acute Wernicke encephalopathy.
  • Magnesium replacement (often deficient; thiamine activity requires magnesium).
  • Supportive care.
  • Recovery of ophthalmoplegia within hours-days; ataxia and confusion may take longer; some deficits irreversible.

Korsakoff Syndrome

Pathology

  • Chronic mammillary body atrophy (often visible at autopsy as brown, shrunken structures).
  • Medial thalamic atrophy.
  • Hippocampal involvement variable.
  • Cortical thinning.

Clinical Features

  • Severe anterograde amnesia: inability to form new memories.
  • Retrograde amnesia: often graded; remote memories better preserved.
  • Confabulation: filling memory gaps with plausible but false information (especially in early stages).
  • Apathy, lack of insight.
  • Preserved attention (distinguishing from delirium).
  • Preserved procedural memory: can learn new skills.
  • Preserved general cognition: IQ relatively preserved.

Diagnosis

Clinical features + history of Wernicke or chronic alcoholism / malnutrition + MRI findings (mammillary body atrophy).

Treatment

  • Thiamine supplementation (continued long-term).
  • Often irreversible.
  • Supportive care; reorientation; structured environment.
  • Sometimes treatment of underlying alcohol dependence.

Other Vitamin Deficiency Encephalopathies

Niacin (B3) Deficiency (Pellagra)

  • Classical triad: dermatitis + diarrhea + dementia.
  • Pathology: cortical dysfunction; selective neuronal damage.
  • Replaced niacin or balanced diet.

Pyridoxine (B6) Deficiency or Toxicity

  • Deficiency: seizures (especially in infants on isoniazid).
  • Toxicity (high-dose B6): sensory neuropathy.

Folate Deficiency

Neural tube defects in pregnancy; rarely encephalopathy. Some cognitive features.

Vitamin B12 Deficiency

Subacute combined degeneration (separate page).

Vitamin D Deficiency

Possibly associated with cognitive impairment; debated.

Vitamin E Deficiency

Sensory ataxia + neuropathy + retinopathy. Treatment with vitamin E.

🔍 Did You Know?

The teaching that thiamine should be administered BEFORE glucose in any patient at risk for Wernicke encephalopathy is one of the most clinically important pharmacologic principles in emergency medicine. Glucose administration in a thiamine-deficient patient can precipitate or worsen Wernicke encephalopathy by accelerating intracellular thiamine consumption — and the consequences can be devastating: irreversible amnesia, ataxia, even death. The mechanism: glucose metabolism requires thiamine as a cofactor (especially for pyruvate dehydrogenase and α-ketoglutarate dehydrogenase in the citric acid cycle). When glucose is administered, the cells try to metabolize it, exhausting whatever residual thiamine is present. The clinical implication: any patient who is alcoholic, malnourished, post-bariatric surgery, with hyperemesis, or otherwise at risk should receive IV thiamine before or simultaneously with any glucose administration. This includes the routine “thiamine before D5W” practice in emergency departments and the now-standard practice of giving thiamine before glucose to comatose patients with possible alcoholism. The dose for prophylaxis is typically 100 mg IV; for treatment of suspected Wernicke encephalopathy, high doses (500 mg IV three times daily) are required. The recognition of this principle — and the integration into ED protocols — has prevented countless cases of permanent Korsakoff syndrome. The lesson: a 5-minute pharmacy intervention can prevent a lifetime of cognitive disability.

Pitfalls and Pearls

  • Wernicke encephalopathy triad: ophthalmoplegia + ataxia + confusion (full triad only ~10%; usually partial).
  • Risk factors: alcoholism, malnutrition, bariatric surgery, hyperemesis, severe illness.
  • Treatment: high-dose IV thiamine (500 mg TID), magnesium replacement.
  • Thiamine BEFORE glucose: critical.
  • Mammillary body involvement: signature pathology + MRI finding.
  • Periaqueductal gray + medial thalamic + floor of 4th ventricle + mammillary bodies: classic distribution.
  • Korsakoff syndrome: chronic amnesia + confabulation + preserved attention; often irreversible.
  • Mammillary body atrophy on MRI: chronic Korsakoff.
  • Confabulation: early Korsakoff feature; “filling gaps.”
  • Preserved procedural memory: Korsakoff patients can learn new motor skills.
  • Pellagra: niacin deficiency; dermatitis + diarrhea + dementia.
  • B6 deficiency: seizures; B6 toxicity: sensory neuropathy.
  • B12 deficiency: subacute combined degeneration (separate page).
  • Vitamin E deficiency: sensory ataxia + neuropathy + retinopathy.

References

  1. Love S, Budka H, Ironside JW, Perry A, eds. Greenfield’s Neuropathology. 9th ed. CRC Press; 2015.
  2. Sechi GP, Serra A. Wernicke’s encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007;6(5):442-455.
  3. Kopelman MD, Thomson AD, Guerrini I, Marshall EJ. The Korsakoff syndrome: clinical aspects, psychology and treatment. Alcohol Alcohol. 2009;44(2):148-154.
  4. Galvin R, Bråthen G, Ivashynka A, Hillbom M, Tanasescu R, Leone MA. EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. Eur J Neurol. 2010;17(12):1408-1418.
  5. Sullivan EV, Pfefferbaum A. Neuroimaging of the Wernicke-Korsakoff syndrome. Alcohol Alcohol. 2009;44(2):155-165.